Sarcomatoid Renal Cell Carcinoma: A Clinical Review. (PubMed, Diagnostics (Basel)) - Sep 16, 2026 - P3 | "Adjuvant pembrolizumab significantly improved disease-free survival in high-risk localised RCC with sarcomatoid features (KEYNOTE-564; NCT03142334). In the metastatic setting, nivolumab plus ipilimumab and pembrolizumab plus axitinib are preferred first-line regimens."
IO biomarker • Journal • Review • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Sarcoma • Solid Tumor • BAP1 • CD8 • CDKN2A • CDKN2B • PAX8 • PD-L1 • TP53 • VIM
|
|
Anna M Czarnecka; Piotr Remiszewski
|